Ausbildung
10/2004 - 05/2011
威尼斯赌博游戏_威尼斯赌博app-【官网】izinstudium?an der medizinischen Universit?t Ulm, Regionalspital Surselva, Switzerland und Texas Heart Institute, Houston, USA

2011
Approbation?

Beruflicher Werdegang
10/2011 – 07/2014
Assistenz?rztin für Urologie, Universit?tsklinik Ulm, Klinik für Urologie und Kinderurologie

08/2014 – 09/2018
Assistenz?rztin für Urologie, Universit?tsklinik Münster, Klinik für Urologie und Kinderurologie

06/2017
Zusatzbezeichnung “威尼斯赌博游戏_威尼斯赌博app-【官网】ikament?se Tumortherapie”

Seit 10/2018
Ober?rztin und Leiterin der medikament?sen Uroonkoilogie, Universit?tsklinikum Augsburg, Klinik für Urologie

Habilitation
11/2017?
Thema:?“Pr?diktive und prognostische Bedeutung molekularer Biomarker bei urologischen Tumorerkrankungen“
Westf?ische Wilhelms-Universit?t Münster

Dissertation
05/2011

Thema: “Der Einfluss des small conductance potassium channel 3 (SK3) auf die Zellmorphologie neuraler Stammzellen und prim?rer hippocampaler Neurone"

Institut für Anatomie und Zellbiologie Universit?t Ulm

Dissertationbetreuer : Prof. Dr. med. Tobias M. B?cker

?

Drittmittel

Anneliese-Pohl-Foundation (Detection of Androgenrezeptor

Modifications in Circulating Tumour Cells; 150.000,- Euro), 2014

Preise
04/2016
Paul-Mellin-Award NRWGU

03/2017
EAU Best Paper on Clinical Research Award 2017

Studienerfahrung
Nierenzellkarzinom:
Checkmate214: Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

KEYNOTE-426: A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) CaboCare: Prospective Non-interventional Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment

Prostatakarzinom:
ERA-223: A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-na?ve Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)

VIABLE: A Randomized, Double Blind, Multicenter, Parallelgroup, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy

PRESIDE: A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Na?ve Metastatic Castration Resistant Prostate Cancer Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone

SPARTAN: A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer

ARAMIS: A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

ARASENS: A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer

ADAM: A Randomized, Open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

Urothelkarzinom:
DANUBE: A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer

KEYNOTE-045: A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel or Vinflunine in Subjects With Recurrent or Progressive Metastatic Urothelial Cancer

KEYNOTE-361: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma

AVENUE: A multi-centre noninterventional study to describe the early clinical experience of Avelumab used as monotherapy for the first line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy.

Mitgliedschaften
European Society for 威尼斯赌博游戏_威尼斯赌博app-【官网】ical Oncology (ESMO)
Deutsche Gesellschaft für Urologie (DGU)
European Association of Urology (EAU)
German Society for Residents in Urology (GeSRU)




?